Maroteaux-Lamy disease (mucopolysaccharidosis VI), subtype A: Deficiency of a N-acetylgalactosamine-4-sulfatase, Biochem Biophys Res Commun, vol.60, pp.1170-1177, 1974. ,
Arylsulfatase B deficiency in Maroteaux-Lamy syndrome cultured fibroblasts, Biochem Biophys Res Commun, vol.59, issue.74, pp.455-461, 1974. ,
The mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease, pp.3421-3452, 2001. ,
, Orphanet J Rare Dis, vol.5, p.20385007, 2010.
Mucopolysaccharidosis VI: pathophysiology, diagnosis and treatment, Front Biosci, vol.22, pp.385-406, 2017. ,
Pathogenesis of skeletal and connective tissue involvement in the mucopolysaccharidoses. Glycosaminoglycan storage is merely the instigator, Rheumatology (Oxford), vol.50, issue.5, pp.13-21, 2011. ,
The clinical spectrum and pathophysiology of skeletal complications in lysosomal storage disorders, Best practice & Research clinical endocrinology & Metabolism, vol.29, pp.219-235, 2015. ,
Cardiac disease in patients with mucopolysaccharidosis. Presentation, diagnosis and management, J Inherit Metab Dis, vol.34, pp.1183-1197, 2011. ,
Cardiovascular manifestations of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome), Int J Cardiol, vol.158, pp.6-11, 2012. ,
Endocardial fibroelastosis in mucopolysaccharidosis type VI, Clin Cardiol, vol.10, pp.362-364, 1987. ,
The ocular features of the mucopolysaccharidoses, Eye (Lond), vol.20, pp.553-563, 2006. ,
Glaucoma in the Maroteaux-Lamy syndrome, Am J Ophthalmol, vol.108, pp.426-430, 1989. ,
Emerging drugs for the treatment of mucopolysaccharidoses, Expert Opin Emerg Drugs, vol.21, pp.9-26, 2016. ,
Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments, Drugs, vol.79, p.31209777, 2019. ,
Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome), J Pediatr, vol.144, pp.574-580, 2004. ,
Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI, Cochrane Database Syst Rev, vol.3, 2016. ,
Ocular manifestations and management recommendations of lysosomal storage disorders I: mucopolysaccharidoses, Clin Ophthalmol, vol.9, pp.1633-1644, 2015. ,
A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis, J Thromb Haemost, vol.4, p.16961606, 2006. ,
Stimulation of synthesis of free chondroitin sulfate chains by beta-D-xylosides in cultured cells, J Biol Chem, vol.250, pp.5400-5406, 1975. ,
Effect of beta-xylosides on synthesis of chondroitin sulfate proteoglycan, chondroitin sulfate chains, and core protein, J Biol Chem, vol.252, pp.6316-6321, 1977. ,
Unusual beta-D-xylosides that prime glycosaminoglycans in animal cells, J Biol Chem, vol.271, pp.19159-19165, 1996. ,
Synthetic Xylosides. Probing the Glycosaminoglycan Biosynthetic Machinery for Biomedical Applications, Acc Chem Res, vol.50, pp.2693-2705, 2017. ,
Synthesis and sorting of proteoglycans, J Cell Sci, vol.113, issue.2, pp.193-205, 2000. ,
Biosynthesis of chondroitin sulfate: interaction between xylosyltransferase and galactosyltransferase, Biochem Biophys Res Commun, vol.56, pp.717-724, 1974. ,
The effect of the beta-D-xyloside naroparcil on circulating plasma glycosaminoglycans. An explanation for its known antithrombotic activity in the rabbit, J Biol Chem, vol.270, pp.2662-2668, 1995. ,
, Transforming Growth Factor-?1-Induced Fibrotic Phenotype in Lung Fibroblasts, PLoS ONE, vol.11, p.146499, 2016.
A mutation in the Arsb gene; a mouse model that resembles Maroteaux-Lamy syndrome, 2009. ,
The Lysosomal Protein Arylsulfatase B Is a Key Enzyme Involved in Skeletal Turnover, J Bone Miner Res, vol.33, pp.2186-2201, 2018. ,
Dimethylmethylene Blue Assay (DMMB), vol.4, p.1236, 2014. ,
Immunocytochemical localization of native chondroitin-sulfate in tissues and cultured cells using specific monoclonal antibody, Cell, vol.38, issue.84, p.6435883, 1984. ,
Subcellular localization of the synthesis and glycosylation of chondroitin sulfate proteoglycan core protein, J Biol Chem, vol.259, pp.7300-7310, 1984. ,
Golgi glycosylation, Cold Spring Harb Perspect Biol, 2011. ,
Biosynthesis and function of chondroitin sulfate, Biochim Biophys Acta, vol.1830, pp.4719-4733, 2013. ,
Targeted disruption of the arylsulfatase B gene results in mice resembling the phenotype of mucopolysaccharidosis VI, Proc Natl Acad Sci U S A, vol.93, pp.8214-8219, 1996. ,
Cardiac and ocular pathologies in a mouse model of mucopolysaccharidosis type VI, Pediatr Res, vol.54, pp.701-708, 2003. ,
Histomorphometric analysis of the tibial growth plate in a feline model of mucopolysaccharidosis type VI, Calcif Tissue Int, vol.65, pp.47-52, 1999. ,
Morphology of leukocytes from cats affected with alpha-mannosidosis and mucopolysaccharidosis VI (MPS VI), Vet Pathol, vol.26, pp.294-302, 1989. ,
Blood film examination for vacuolated lymphocytes in the diagnosis of metabolic disorders; retrospective experience of more than 2,500 cases from a single centre, J Clin Pathol, vol.58, pp.1305-1310, 2005. ,
Further studies on the mechanism for the antithrombotic effects of naroparcil, an orally active thioxyloside compound, Thromb Haemost, vol.81, pp.945-950, 1999. ,
Characterization of total plasma glycosaminoglycan levels in healthy volunteers following oral administration of a novel antithrombotic odiparcil with aspirin or enoxaparin, J Clin Pharmacol, vol.48, pp.1158-1170, 2008. ,
Tumor attenuation by 2(6-hydroxynaphthyl)-beta-D-xylopyranoside requires priming of heparan sulfate and nuclear targeting of the products, Glycobiology, vol.14, pp.387-397, 2004. ,
Xyloside-primed Chondroitin Sulfate/Dermatan Sulfate from Breast Carcinoma Cells with a Defined Disaccharide Composition Has Cytotoxic Effects in Vitro, J Biol Chem, vol.291, pp.14871-14882, 2016. ,
A glycan-based approach to therapeutic angiogenesis, PLoS ONE, vol.12, p.182301, 2017. ,
Increased axon regeneration in astrocytes grown in the presence of proteoglycan synthesis inhibitors, J Cell Sci, vol.108, pp.1307-1315, 1995. ,
Exogenous addition of a C-xylopyranoside derivative stimulates keratinocyte dermatan sulfate synthesis and promotes migration, PLoS ONE, vol.6, 2011. ,
A modified liquid chromatography/tandem mass spectrometry method for predominant disaccharide units of urinary glycosaminoglycans in patients with mucopolysaccharidoses, Orphanet J Rare Dis, vol.9, p.25178307, 2014. ,
A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: an improved clinical screening test for the mucopolysaccharidoses, Mol Genet Metab, vol.114, pp.123-128, 2015. ,
Lysosomal Storage Diseases, Journal of Inborn Errors of Metabolism and Screening, vol.2, pp.1-20, 2014. ,
Enzyme Replacement Therapy With Elosulfase Alfa Decreases Storage of Glycosaminoglycan in White Blood Cells of Patients With Morquio A Syndrome, Journal of Inborn Errors of Metabolism and Screening, vol.3, pp.1-3, 2015. ,
Enzyme replacement therapy in Mucopolysaccharidosis VI: evidence for immune responses and altered efficacy of treatment in animal models, Biochim Biophys Acta, vol.1361, pp.36-43, 1997. ,
Allo-immune membranous nephropathy and recombinant aryl sulfatase replacement therapy: a need for tolerance induction therapy, J Am Soc Nephrol, vol.25, pp.675-680, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-02191546
Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome, J Clin Invest, vol.97, pp.1864-1873, 1996. ,
Enzyme replacement therapy in mice lacking arylsulfatase B targets bone remodeling cells, but not chondrocytes, Hum Mol Genet, 2020. ,
Enzyme replacement therapy in feline mucopolysaccharidosis I, Mol Genet Metab, vol.72, pp.199-208, 2001. ,
Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction, Mol Genet Metab, vol.117, pp.66-83, 2016. ,
Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models, Pediatr Res, vol.57, pp.701-707, 2005. ,
Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities, Am J Pathol, vol.175, pp.2053-2062, 2009. ,
Progressive heart disease in mucopolysaccharidosis type I mice may be mediated by increased cathepsin B activity, Cardiovasc Pathol, vol.27, pp.45-50, 2017. ,
Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses, Proc Natl Acad Sci U S A, vol.107, pp.222-227, 2010. ,
Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI, PLoS ONE, vol.6, 2011. ,
Chondroitin sulfate and growth factor signaling in the skeleton. Possible links to MPS VI, J Pediatr Rehabil Med, vol.3, pp.129-138, 2010. ,
A New C-Xyloside induces modifications of GAG expression, structure and functional properties, PLoS ONE, vol.7, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00871190
Fine-tuning the structure of glycosaminoglycans in living cells using xylosides, Glycobiology, vol.28, pp.499-511, 2018. ,
Heparin cofactor IIthrombin complex: a biomarker of MPS disease, Mol Genet Metab, vol.94, pp.456-461, 2008. ,
LC-MS/MS characterization of xyloside-primed glycosaminoglycans with cytotoxic properties reveals structural diversity and novel glycan modifications, J Biol Chem, 2018. ,